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of 54°C, and 45 ampliﬁ  cation cycles. 
PCR blanks containing all reagents 
except for DNA and extraction blanks 
were included in every PCR set.
Results of the ampliﬁ  cation  re-
actions are listed in the Table. All 
accompanied extraction and PCR 
controls remained free of ampliﬁ  ca-
tion products. All amplicons resulting 
from suicide PCRs were sequenced. 
Amplicons resulting from the use 
of primer pairs YP14F/YP13R and 
pst-F/pst-R matched the reference 
sequence to 100% (GenBank acces-
sion no. AL109969.1). Amplicons 
resulting from the use of primer pair 
PCP-F/PCP-R matched this reference 
sequence to only 97.78%. This devia-
tion is because of a 2-bp insertion (2 
Ts, positions 8531 and 8532, GenBank 
accession no. AL109969.1) at Y. pestis 
strain CO92 plasmid pPCP1. The se-
quences obtained from 3 persons’ re-
mains showed in the pPCP1 sequence 
section between nucleotide positions 
8528–8532 only 3 Ts instead of 5 Ts 
described for Y. pestis strain CO92 
plasmid pPCP1 (GenBank accession 
no. AL109969.1). The sequences 
found in this study were deposited 
in GenBank under accession nos. 
HQ290521–HQ290523.
To conclude, the successful re-
covery of several Y. pestis plasmid 
pPCP1 DNA sequences in skeletal 
ﬁ   nds from the mass burial site ex-
cavated in Manching-Pichl suggests 
that these persons died of plague. 
Moreover, our ﬁ   ndings constitute a 
molecularly supported conﬁ  rmation 
for the presence of Y. pestis, the etio-
logic agent of plague, in late medieval 
(1250–1500  CE) southern Germany. 
In future studies, we will attempt to 
recover chromosomal Y. pestis DNA 
from the mass grave skeletal remains 
to obtain clues as to the speciﬁ  c Y. 
pestis strain and the microbiology of 
past plague in Europe. 
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Two Clusters of 
HIV-1 Infection, 
Rural Idaho, 
USA, 2008
To the Editor: Prevalence of 
HIV-1 infection in rural areas of the 
United States has been increasing (1). 
During 2003–2007, an average of 30 
(range 24–42) cases of new HIV-1 
infection diagnoses per year among 
Idaho residents were reported. Of the 
152 reported cases during this period, 
54 (36%) were related to a person liv-
ing in a rural area of <75,000 residents 
and a 60-minute drive from an urban 
area (2). Of these 54 cases, 19 (35%) 
were in men who have sex with men 
(MSM), 5 (9%) were in injection drug 
users (IDU), and 2 (4%) were in those 
in both categories.
In March 2008, a cluster of newly 
identiﬁ   ed HIV-1 infections that in-
cluded 5 cases (cluster A) in a rural 
southeastern Idaho city (city A) was 
reported to the Idaho Department of 
Health and Welfare. Two patients 
were men and the median age was 26 
years (range 18–32 years). One patient 
was an IDU (Table). Through epide-
miologic investigation, 3 additional 
patients were suspected to be IDUs, 
but conﬁ  rmation was not practicable. 
All reported methamphetamine use. 
One man and 2 women reported both 
male and female sex partners.
During September–December of 
that year, another increase in newly 
identiﬁ  ed HIV-1 infections in south-
eastern Idaho (cluster B) was reported 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 11, November 2010  1807 LETTERS
to Idaho Department of Health and 
Welfare. Cluster B included 10 cases, 
all among men who reported living 
within a 50-mile radius of city A, with 
most in a rural city (city B) located 
<30 miles from city A. The median age 
of the men in cluster B was 24 years 
(range 18–37 years). Each case was 
epidemiologically linked to at least 1 
other case in the cluster; each patient 
reported having had unprotected sex 
with male partners. Although we sus-
pected transmission of HIV-1 between 
persons in clusters A and B, whether 
the clusters were linked epidemiologi-
cally remained unclear after an initial 
investigation.
Although the primary use of 
HIV-1 sequence data is to assist cli-
nicians in selecting antiretroviral 
(ARV) therapy, public health prac-
titioners can use HIV-1 sequences 
from cases and compare those with 
HIV-1 sequences from others living 
in the region to explore phyloge-
netic associations and possible HIV 
transmission clusters (3). To evalu-
ate links between clusters A and B, 
HIV-1 pol consensus sequence data 
for 4 of the 5 cases from cluster A 
and 6 of the 10 cases from cluster 
B were obtained from 5 commercial 
laboratories. No case-patients had 
received ARV. Additionally, we used 
sequence data from a patient residing 
in city B who had received an HIV-1 
diagnosis in December 2008 but was 
not epidemiologically linked to ei-
ther cluster. HIV-1 control sequences 
from 2 Idaho HIV clinics, including 
34 HIV-1–infected persons within a 
275-mile radius of city B identiﬁ  ed 
who had not received ARV and who 
had resistance testing performed dur-
ing 2005–2008, were used to repre-
sent the regional epidemic. Control 
sequences were aligned with cluster 
A and B sequences and analyzed as 
described (4,5).
Ten of the HIV case-patients for 
whom nucleotide sequence data were 
obtained were infected with HIV-1, 
subtype B, and were placed into 2 dis-
tinct phylogenetic-related groupings. 
Group 1 contained 4 patients from 
cluster A and 1 patient with no known 
epidemiologic link to either cluster. 
Group 2 contained 5 patients from 
cluster B. The average pol genetic dis-
tance among virus from members of 
group 1 was 0.2% (median 0.1%, SD 
0.2%) and from members of group 2 
was 0.1% (median 0.1%, SD 0.1%). 
The average distance among the con-
trol sequences was 5.1% (median 
5.2%, SD 1.2%). The average distance 
between groups 1 and 2 was 4.8% 
(median 4.8%, SD 0.2%), which does 
not demonstrate a linkage between the 
2 groups. The 1 case in group 1 that 
was not initially identiﬁ   ed with ei-
ther cluster had a genetically related 
HIV-1 sequence to members of cluster 
A, indicating a potential previously 
unidentiﬁ   ed epidemiologic link. The 
sequence from 1 case associated with 
cluster B was not genetically similar 
to members of either cluster and was 
more similar to controls. These data 
do not indicate from whom each pa-
tient acquired the infection.
The epidemiologic investigation 
combined with the molecular analysis 
shows transmission of HIV-1 originat-
ing from 2 sources occurred within a 
group of rural MSM in southeastern 
Idaho and indicates a separate case 
previously believed to be unrelated to 
2 local clusters had genetic similarity 
to cluster A. Limitations of this inves-
tigation include the inability to obtain 
HIV sequences from all persons iden-
tiﬁ  ed in clusters A and B and an inabil-
ity to conﬁ  rm high-risk behaviors for 
all identiﬁ  ed case-patients.
Previous HIV clusters have dem-
onstrated that infectious persons can 
spread HIV quickly within a social 
network and highlighted the impor-
tance of timely prevention activities to 
limit HIV transmission in a commu-
nity (6,7). Use of phylogenetic analy-
sis of HIV-1 sequences obtained from 
commercial laboratories showed that 
clusters A and B were not epidemio-
logically related and helped target ap-
propriate and speciﬁ  c HIV prevention 
activities.
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Table. Sex and risk factors among patients epidemiologically linked to 2 clusters of  
HIV-1, southeastern Idaho, USA, 2008* 
Case ID Sex Risk factors Cluster† Phylogenetic group
1 F WSMW/SIDU A 1
2 F WSMW/SIDU A 1
3 M MSMW/IDU A 1
4‡ M MSW A ND 
5 M MSM B 2
6‡ M MSM B ND 
7‡ M MSM B ND 
8‡ M MSM B ND 
9 M MSM B 2
10§ M MSM B ND 
11 M MSM B 2
12‡ M MSM B ND 
13 M MSM B 2
14 FW S M  A 1
15 M MSM B 2
16¶ M MSM ND 1
*ID, identification; WSMW, women who have sex with men and women; SIDU, sex with injection 
drug users; MSMW, men who have sex with men and women; IDU, injection drug user; MSW, men 
who have sex with women; ND, not determined; MSM, men who have sex with men; WSM, women 
who have sex with men. 
†Cluster A associated with injection drug use; cluster B associated with MSM. 
‡HIV-1 sequence was not available for molecular analysis. 
§HIV-1 sequence was similar to controls but not to sequences from either cluster A or B. 
¶Case with no epidemiologic link to cluster A or cluster B. LETTERS
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Pandemic (H1N1) 
2009 and 
Oseltamivir 
Resistance in 
Hematology/
Oncology Patients
To the Editor: Tramontana et 
al. (1) recently described character-
istics and oseltamivir resistance in 
hematology and oncology patients 
infected with pandemic (H1N1) 2009 
virus. Such cases merit further study 
because concurrent medical prob-
lems in immunosuppressed patients 
may obscure and delay diagnosis and 
management of pandemic (H1N1) 
2009 infections. Moreover, severe 
complications of such infection may 
be more likely to develop in immu-
nosuppressed patients (2). During the 
winter of 2009, oseltamivir-resistant 
pandemic (H1N1) 2009 virus infec-
tion was diagnosed for 4 patients at 
Duke University Medical Center. We 
describe the clinical features of the 
infections, the challenges associated 
with diagnosis of pandemic (H1N1) 
2009 virus infection, and the clinical 
outcome for the infected patients.
Four immunocompromised pa-
tients who received chemotherapy and 
immunotherapy for solid-organ and 
hematologic malignancies were hospi-
talized at our tertiary care medical cen-
ter during October–November 2009, a 
period of peak activity of pandemic 
(H1N1) 2009 in surrounding commu-
nities in North Carolina (3). These 4 
case-patients experienced symptoms 
attributable to pandemic (H1N1) 2009 
from 0 to 14 days after hospital admis-
sion, and the diagnosis of pandemic 
(H1N1) 2009 was made 0–28 days af-
ter symptom onset. Illness, diagnosis, 
and treatment of the patients are sum-
marized in the Table. One patient re-
ported contact with a family member 
who had inﬂ  uenza-like illness. Three 
other patients likely acquired pandem-
ic (H1N1) 2009 in the hospital. An 
investigation could not conclusively 
establish whether transmission of pan-
demic (H1N1) 2009 occurred between 
case-patients and healthcare workers 
or visitors (4). All 4 case-patients ulti-
mately died; 2 patients recovered from 
pandemic (H1N1) 2009 after antiviral 
drug therapy but died of underlying 
disease and subsequent bacterial infec-
tions. One case-patient did not receive 
antiviral drugs because the diagnosis 
was made posthumously.
We learned valuable lessons re-
garding diagnosis and management of 
pandemic (H1N1) 2009 in immuno-
compromised patients. First, pandemic 
(H1N1) 2009 infection can be difﬁ  cult 
to diagnose in immunocompromised 
hospitalized patients. Such patients 
do not exhibit consistent symptoms 
or signs for pandemic (H1N1) 2009. 
Consistent with Tramontana et al. (1), 
fever was the most common feature, 
followed by progressive dyspnea and 
intermittent cough. None of our pa-
tients reported sore throat. Moreover, 
such nonspeciﬁ   c symptoms may be 
inadvertently attributed to concurrent 
medical problems common in immu-
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